Partager:

Vice President (Vice President) Ma'ruf Amin admitted that the government will continue to investigate the source of new cases of acute progressive kidney disorders (GGAPA) in children in the country.

"We have asked the Ministry of Health and the POM to continue to supervise and control it, if it is not a sirop drug, find more sources, see you," he said in Central Lombok, West Nusa Tenggara (NTB), Friday, February 10, as reported by Antara.

Previously, a one-year-old child in Jakarta who was confirmed to have failed to die in early February 2023.

The case began when the victim had a fever on January 25, 2023 and was given a fever-depletion mild drug purchased at a pharmacy with the Praxion brand.

"We also ask the Ministry of Health to support the affected people, to come and encourage them (to) support the people affected by the disease, the victims and continue to investigate what caused this, the government continues like that," said the Vice President.

The Food and Drug Supervisory Agency (BPOM) has also announced that Praxion▁Sedangkand drugs are safe for consumption based on a series of tests.

However, BPOM has ordered the temporary suspension of the production and distribution of drugs consumed by patients confirmed to have died due to experiencing GGAPA on February 4, 2023.

PT Pharos Indonesia also voluntarily withdrew, recalled, Praxion sirop drug products from related batches as the responsibility of the pharmaceutical industry.

To ensure product quality and safety, PT Pharos Indonesia also conducted examinations at three accredited external laboratories. The results of this examination will be obtained in the next few days.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)